Companies Dominating the Neuroblastoma Drugs Landscape
- CELLECTAR BIOSCIENCES, INC.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- APEIRON Biologics AG
- Pfizer Inc.
- Eli Lilly and Company
- AstraZeneca
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- MacroGenics Inc.
- Marsala Biotech Inc.
- Johnson & Johnson Services, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of neuroblastoma drugs is estimated at USD 276.84 billion.
The neuroblastoma drugs market size was valued at USD 254.78 billion in 2024 and is set to exceed USD 498.58 billion by 2037, expanding at over 5.3% CAGR during the forecast period i.e., between 2025-2037. Increasing the practice of chemotherapy, and a high number of people with early diagnosis test awareness will boost the market growth.
North America industry is estimated to hold largest revenue share of 36% by 2037, due to rise in technologically enhanced drugs along with the increase in incidences of neuroblastoma.
The major players in the market are CELLECTAR BIOSCIENCES, INC., APEIRON Biologics AG, Pfizer Inc., Eli Lilly and Company, AstraZeneca, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, MacroGenics Inc., Marsala Biotech Inc., Johnson & Johnson Services, Inc.
